{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:10:17Z","timestamp":1793823017523,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI124377, AI128751, AI145801, AI149670, AI164556, AI169615, AI177687"],"award-info":[{"award-number":["AI124377, AI128751, AI145801, AI149670, AI164556, AI169615, AI177687"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41591-024-03247-5","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T14:03:50Z","timestamp":1726495430000},"page":"3534-3543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-9626","authenticated-orcid":false,"given":"Boris","family":"Julg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7847-7931","authenticated-orcid":false,"given":"Victoria E. K.","family":"Walker-Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7552-6582","authenticated-orcid":false,"given":"Kshitij","family":"Wagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-7893","authenticated-orcid":false,"given":"Malika","family":"Aid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3440-4105","authenticated-orcid":false,"given":"Kathryn E.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Zash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Nkolola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1307-2508","authenticated-orcid":false,"given":"Amelia","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8045-1754","authenticated-orcid":false,"given":"Mike","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Serebryannyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Yanosick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Speidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica N.","family":"Borducchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-1784","authenticated-orcid":false,"given":"Tetyana","family":"Murzda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7595-6205","authenticated-orcid":false,"given":"Lori","family":"Maxfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7381-844X","authenticated-orcid":false,"given":"Roberto","family":"Arduino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-9117","authenticated-orcid":false,"given":"Adrian B.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena E.","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte-Paige","family":"Rolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"DeJesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-7386","authenticated-orcid":false,"given":"Wenjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-5757","authenticated-orcid":false,"given":"Bette","family":"Korber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5127-4659","authenticated-orcid":false,"given":"Dan H.","family":"Barouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"3247_CR1","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","volume":"27","author":"KE Stephenson","year":"2021","unstructured":"Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat. Med. 27, 1718\u20131724 (2021).","journal-title":"Nat. Med."},{"key":"3247_CR2","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","volume":"24","author":"Y Bar-On","year":"2018","unstructured":"Bar-On, Y. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat. Med. 24, 1701\u20131707 (2018).","journal-title":"Nat. Med."},{"key":"3247_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","volume":"606","author":"C Gaebler","year":"2022","unstructured":"Gaebler, C. et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature 606, 368\u2013374 (2022).","journal-title":"Nature"},{"key":"3247_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","volume":"606","author":"MC Sneller","year":"2022","unstructured":"Sneller, M. C. et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature 606, 375\u2013381 (2022).","journal-title":"Nature"},{"key":"3247_CR5","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","volume":"28","author":"B Julg","year":"2022","unstructured":"Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288\u20131296 (2022).","journal-title":"Nat. Med."},{"key":"3247_CR6","doi-asserted-by":"publisher","first-page":"e1005520","DOI":"10.1371\/journal.ppat.1005520","volume":"12","author":"K Wagh","year":"2016","unstructured":"Wagh, K. et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection. PLoS Pathog. 12, e1005520 (2016).","journal-title":"PLoS Pathog."},{"key":"3247_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","volume":"38","author":"KE Stephenson","year":"2020","unstructured":"Stephenson, K. E., Wagh, K., Korber, B. & Barouch, D. H. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Annu. Rev. Immunol. 38, 673\u2013703 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"3247_CR8","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","volume":"7","author":"RM Lynch","year":"2015","unstructured":"Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).","journal-title":"Sci. Transl. Med."},{"key":"3247_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185\u2013191 (2017).","journal-title":"Nat. Med."},{"key":"3247_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487\u2013491 (2015).","journal-title":"Nature"},{"key":"3247_CR11","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","volume":"6","author":"TA Crowell","year":"2019","unstructured":"Crowell, T. A. et al. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV 6, e297\u2013e306 (2019).","journal-title":"Lancet HIV"},{"key":"3247_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"3247_CR13","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41591-023-02547-6","volume":"29","author":"JD Gunst","year":"2023","unstructured":"Gunst, J. D. et al. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nat. Med. 29, 2547\u20132558 (2023).","journal-title":"Nat. Med."},{"key":"3247_CR14","doi-asserted-by":"publisher","first-page":"101475","DOI":"10.1016\/j.smim.2021.101475","volume":"51","author":"B Julg","year":"2021","unstructured":"Julg, B. & Barouch, D. Broadly neutralizing antibodies for HIV-1 prevention and therapy. Semin. Immunol. 51, 101475 (2021).","journal-title":"Semin. Immunol."},{"key":"3247_CR15","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1093\/cid\/ciac164","volume":"75","author":"C Wang","year":"2022","unstructured":"Wang, C. et al. Landscape of human immunodeficiency virus neutralization susceptibilities across tissue reservoirs. Clin. Infect. Dis. 75, 1342\u20131350 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"3247_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003\u20131014 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3247_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.chom.2018.12.001","volume":"25","author":"CA Bricault","year":"2019","unstructured":"Bricault, C. A. et al. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 25, 59\u201372 e58 (2019).","journal-title":"Cell Host Microbe"},{"key":"3247_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2016.06.026","volume":"45","author":"D Sok","year":"2016","unstructured":"Sok, D. et al. A prominent site of antibody vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging glycans. Immunity 45, 31\u201345 (2016).","journal-title":"Immunity"},{"key":"3247_CR19","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1074\/jbc.RA118.005396","volume":"294","author":"SW de Taeye","year":"2019","unstructured":"de Taeye, S. W. et al. Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. J. Biol. Chem. 294, 5616\u20135631 (2019).","journal-title":"J. Biol. Chem."},{"key":"3247_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","volume":"563","author":"EN Borducchi","year":"2018","unstructured":"Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360\u2013364 (2018).","journal-title":"Nature"},{"key":"3247_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31196-5","volume":"13","author":"VEK Walker-Sperling","year":"2022","unstructured":"Walker-Sperling, V. E. K. et al. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques. Nat. Commun. 13, 3463 (2022).","journal-title":"Nat. Commun."},{"key":"3247_CR22","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41591-023-02570-7","volume":"29","author":"A Dashti","year":"2023","unstructured":"Dashti, A. et al. AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques. Nat. Med. 29, 2535\u20132546 (2023).","journal-title":"Nat. Med."},{"key":"3247_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature21435","volume":"543","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559\u2013563 (2017).","journal-title":"Nature"},{"key":"3247_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157\u2013159 (2010).","journal-title":"Nat. Biotechnol."},{"key":"3247_CR25","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/infdis\/jiac041","volume":"226","author":"S Mahomed","year":"2022","unstructured":"Mahomed, S. et al. Safety and pharmacokinetics of monoclonal antibodies VRC07-523LS and PGT121 administered subcutaneously for human immunodeficiency virus prevention. J. Infect. Dis. 226, 510\u2013520 (2022).","journal-title":"J. Infect. Dis."},{"key":"3247_CR26","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1073\/pnas.0802203105","volume":"105","author":"BF Keele","year":"2008","unstructured":"Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552\u20137557 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3247_CR27","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1128\/JVI.02108-09","volume":"84","author":"MS Seaman","year":"2010","unstructured":"Seaman, M. S. et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439\u20131452 (2010).","journal-title":"J. Virol."},{"key":"3247_CR28","doi-asserted-by":"crossref","unstructured":"Montefiori, D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. Chapter 12, 12.11.1\u201312.11.17 (2005).","DOI":"10.1002\/0471142735.im1211s64"},{"key":"3247_CR29","doi-asserted-by":"publisher","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","volume":"79","author":"M Li","year":"2005","unstructured":"Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108\u201310125 (2005).","journal-title":"J. Virol."},{"key":"3247_CR30","doi-asserted-by":"publisher","first-page":"11776","DOI":"10.1128\/JVI.01730-06","volume":"80","author":"M Li","year":"2006","unstructured":"Li, M. et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80, 11776\u201311790 (2006).","journal-title":"J. Virol."},{"key":"3247_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","volume":"566","author":"KM Bruner","year":"2019","unstructured":"Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566, 120\u2013125 (2019).","journal-title":"Nature"},{"key":"3247_CR32","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1089\/aid.1995.11.1413","volume":"11","author":"AC Siepel","year":"1995","unstructured":"Siepel, A. C., Halpern, A. L., Macken, C. & Korber, B. T. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res. Hum. Retroviruses 11, 1413\u20131416 (1995).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"3247_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.chom.2018.12.001","volume":"25","author":"CA Bricault","year":"2019","unstructured":"Bricault, C. A. et al. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 25, 59\u201372.e8 (2019).","journal-title":"Cell Host Microbe"},{"key":"3247_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/sysbio\/syq010","volume":"59","author":"S Guindon","year":"2010","unstructured":"Guindon, S. et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol. 59, 307\u2013321 (2010).","journal-title":"Syst. Biol."},{"key":"3247_CR35","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1128\/JVI.80.10.5074-5077.2006","volume":"80","author":"LJ Yant","year":"2006","unstructured":"Yant, L. J. et al. The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 80, 5074\u20135077 (2006).","journal-title":"J. Virol."},{"key":"3247_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nature10766","volume":"482","author":"DH Barouch","year":"2012","unstructured":"Barouch, D. H. et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, 89\u201393 (2012).","journal-title":"Nature"},{"key":"3247_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nature20583","volume":"540","author":"EN Borducchi","year":"2016","unstructured":"Borducchi, E. N. et al. Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature 540, 284\u2013287 (2016).","journal-title":"Nature"},{"key":"3247_CR38","doi-asserted-by":"publisher","first-page":"28232","DOI":"10.1073\/pnas.2013554117","volume":"117","author":"AA Bashirova","year":"2020","unstructured":"Bashirova, A. A. et al. HLA tapasin independence: broader peptide repertoire and HIV control. Proc. Natl Acad. Sci. USA 117, 28232\u201328238 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03247-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03247-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03247-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T08:04:13Z","timestamp":1734077053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03247-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3247"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03247-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"20 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.J. is a part-time employee of Leyden Labs, B.V. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}